5 results
The objective is to investigate the accuracy, feasibility and safety of FFR in patients presenting with STEMI and MVD.
Primary Objective:to clinically use and validate the optimized Raman probe in a patient database in order to differentiate between benign and malignant bladder lesions in vivo.Secondary objective:to develop an algorithm to predict tumor grade in…
Primary objective:To determine the MTD/recommended dose for further study of oral LOXO-292 in patients with advanced solid tumors, including RET-fusion NSCLC, MTC, and other tumors with increased RET activity.Secondary objectives:* To determine the…
Primary* To compare TFFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib.Secondary* To compare other efficacy outcomes, based on RECIST 1.1 criteria, observed in…
To compare PFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib.